Across TCGA pan-cancer cohorts, SNX18P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SNX18P2’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where SNX18P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNX18P2 is over-expressed in tumor.
LUAD and LUSC are the cancer types where SNX18P2 tumor–normal differential expression is most reproducible.